TGM2 and cranioectodermal dysplasia: TG2 is a central player in the pathogenesis of CeD, both as the target of disease‐specific autoantibodies and as the enzyme that catalyzes deamidation of gluten peptides, a modification that is necessary for activation of the disease‐driving gluten‐specific CD4+ T cells [2].